Guidelines for the assessment of cardiovascular risk remainfocused squarely on established risk factors.1 Although it isknown that tools based on these risk factors, such as the FraminghamRisk Score, have a number of limitations when applied in clinicalpractice — performing reasonably well for groups but notnecessarily for individuals and underestimating long-term riskamong younger persons2 — it has proved surprisingly difficultto improve on established risk factors for the prediction ofcardiovascular disease. Of the many strategies that have beenproposed to improve risk stratification, the measurement ofplasma biomarkers is particularly attractive as compared with. . . [Full Text of this Article]
Source Information
From the Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas (J.A.L.); and the Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago (D.M.L.-J.).
This article has been cited by other articles:
Greco, T. P., Conti-Kelly, A. M., Greco, T. Jr, Doyle, R., Matsuura, E., Anthony, J. R., Lopez, L. R.
(2009). Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome. Am J Clin Pathol
132: 613-620
[Abstract][Full Text]
Melander, O., Newton-Cheh, C., Almgren, P., Hedblad, B., Berglund, G., Engstrom, G., Persson, M., Smith, J. G., Magnusson, M., Christensson, A., Struck, J., Morgenthaler, N. G., Bergmann, A., Pencina, M. J., Wang, T. J.
(2009). Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. JAMA
302: 49-57
[Abstract][Full Text]
Shah, S. H., de Lemos, J. A.
(2009). Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment. JAMA
302: 92-93
[Full Text]
(2008). Cardiovascular Risk Prediction: Beyond the Established Risk Factors. Journal Watch Cardiology
2008: 3-3
[Full Text]